CalciMedica is trading 5.5% lower at $1.20, with no clear company-specific announcement explaining the decline.

  • Broad market indexes were mixed, rather than showing a significant decline in the same direction.
  • A September 30 filing permits up to $25 million in stock sales through an at-the-market offering, which could dilute shareholders. The filing predates the move, and available sources do not establish it as the cause.